ased on our results in the LCMV model of viral infection as well as in human HCV Infection it seems likely that viral escape mutations and a combination of molecules associated with T-cell dysfunction and inhibition are key contributors to viral persistence. Importantly, data in acute HCV infection indicate that HCV infection elicits both CD4 and CD8 T cell responses detectable in PBMC during early disease, but the responses decline quickly in persons who progress to chronic infection. In the liver, responses remain detectable, often for decades and at substantial frequencies, yet virus persists at high levels. Our overall hypothesis is that T-cell dysfunction is a major factor in failure to control HCV infection and that by combining both mouse and human studies of T cell dysfunction we can define key pathways or immunological defects underlying poor immunological control of HCV infection. To test this hypothesis we propose to further define the different subsets of T-cells associated with different levels of viral control with experiments in humans and mice informing each other. We will define the functional profile and expressions of a combination of inhibitory molecules using HCV-specific T-cells in human PBMC and liver derived T-cells based on recent findings in LCMV. In parallel we will further refine our murine model by differentiating in detail the transcriptional profiles of T-cells in different stages of dysfunction and different T-cell subsets. We will also establish transcription profiles of human T-cells and the datasets together will direct the future direction of our investigations. In addition to defining the properties of HCV-specific T-cells we will define how the liver environment in chronic HCV infection contributes to T-cell dysfunction and thus viral persistence, e.g. by the expression of T-cell inhibitory ligands or regulatory cytokines. In addition we will also investigate HCV-specific CD4+ T-cells that are equally critical for viral control but have been investigated in much less detail. These studies will be critical for understanding HCV pathogenesis, for guiding the design of prophylactic vaccines and immunotherapeutic interventions, but also for improved general model of persistent viral infections in humans.

Public Health Relevance

More than 170 million persons worldwide are infected with the hepatitis C virus (HCV), with increasing burden of HCV-related liver disease in both developed and developing countries. Despite recent improvements in HCV treatment, only a small fraction of HCV infected persons are cured by currently available treatment regimens. It seems evident that better understanding and treatment will depend on a comprehensive and interconnected approach combining appropriate animal models with their advantage of highly specific experimental interventions with complementary experiments studying human material.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI082630-05
Application #
8475546
Study Section
Special Emphasis Panel (ZAI1-KS-I)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
5
Fiscal Year
2013
Total Cost
$434,131
Indirect Cost
$115,198
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Lin, Wenyu; Zhu, Chuanlong; Hong, Jian et al. (2015) The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing. J Hepatol 62:1024-32
Jilg, Nikolaus; Lin, Wenyu; Hong, Jian et al. (2014) Kinetic differences in the induction of interferon stimulated genes by interferon-* and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 59:1250-61
Kroy, Daniela C; Ciuffreda, Donatella; Cooperrider, Jennifer H et al. (2014) Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 146:550-61
Lee, Mark N; Ye, Chun; Villani, Alexandra-ChloƩ et al. (2014) Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science 343:1246980
Crawford, Alison; Angelosanto, Jill M; Kao, Charlly et al. (2014) Molecular and transcriptional basis of CD4? T cell dysfunction during chronic infection. Immunity 40:289-302
Feeney, Eoin R; Chung, Raymond T (2014) Antiviral treatment of hepatitis C. BMJ 348:g3308
Fackler, Oliver T; Murooka, Thomas T; Imle, Andrea et al. (2014) Adding new dimensions: towards an integrative understanding of HIV-1 spread. Nat Rev Microbiol 12:563-74
Xiao, Yanping; Yu, Sanhong; Zhu, Baogong et al. (2014) RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med 211:943-59
Veerapu, Naga Suresh; Park, Su-Hyung; Tully, Damien C et al. (2014) Trace amounts of sporadically reappearing HCV RNA can cause infection. J Clin Invest 124:3469-78
Ussher, James E; Bilton, Matthew; Attwod, Emma et al. (2014) CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. Eur J Immunol 44:195-203

Showing the most recent 10 out of 72 publications